Updated Jul 16, 2026 · Last SEC filing 2026-06-11
Voyager Therapeutics, Inc. (VYGR) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-11. 5 Form 8-K material event filings were reported by VYGR in the last 90 days. 2 Form 144 notices of proposed sale were filed for VYGR stock. InsiderAlpha tracks every VYGR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001640266 |
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-06-11 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO | S — Open-market sale | 11.5K | $3.87 | $45K | SEC | |
| Shiferman Gregory L. | SVP and General Counsel | A — Grant or award | 50.0K | $0.00 | — | SEC | |
| Carter Todd Alfred | Chief Scientific Officer | S — Open-market sale | 4.2K | $3.76 | $16K | SEC | |
| Swartz Robin | COO & CBO | S — Open-market sale | 6.5K | $3.77 | $24K | SEC | |
| Sandrock Alfred | President and CEO | S — Open-market sale | 14.2K | $3.79 | $54K | SEC | |
| Jorgensen Nathan D. | Chief Financial Officer | S — Open-market sale | 4.7K | $3.77 | $18K | SEC | |
| Carter Todd Alfred | Chief Scientific Officer | S — Open-market sale | 3.3K | $3.44 | $11K | SEC | |
| Sandrock Alfred | President and CEO | S — Open-market sale | 11.7K | $3.41 | $40K | SEC | |
| Swartz Robin | COO & CBO | S — Open-market sale | 3.9K | $3.44 | $13K | SEC | |
| Carter Todd Alfred | Chief Scientific Officer | S — Open-market sale | 3.5K | $3.85 | $14K | SEC | |
| Swartz Robin | COO & CBO | S — Open-market sale | 4.6K | $3.85 | $18K | SEC | |
| Sandrock Alfred | President and CEO | S — Open-market sale | 12.2K | $3.78 | $46K | SEC | |
| Swartz Robin | COO & CBO | A — Grant or award | 45.0K | $0.00 | — | SEC | |
| Jorgensen Nathan D. | Chief Financial Officer | A — Grant or award | 32.2K | $0.00 | — | SEC | |
| Sandrock Alfred | President and CEO | A — Grant or award | 86.2K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Voyager Therapeutics, Inc. (VYGR). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Onyia Jude | 1 | — |
| SCANGOS GEORGE A | 1 | — |
| GERAGHTY JAMES A | 1 | — |
| PIERCE GLENN | 1 | — |
| MACKEY CATHERINE J | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VYGR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live VYGR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.